Loading…
Hyperfine, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -91.9% over 5Y.
today you would have $82.15▼ -91.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $0.98 | $0.88 | $1.12 | $0.84 | $7.25 | |
| P/S | 7.2x | 5.9x | 4.9x | 7.2x | 8.7x | 17.9x |
| P/B | 0.9x | 2.0x | 1.3x | 0.9x | 0.5x | 0.1x |
| EPS | -$0.43 | -$0.56 | -$0.62 | -$1.04 | -$17.57 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATRAAtara Biotherapeutics, Inc. | $8.81 | — | — | — | — | $88.43M |
| GUTSFractyl Health Inc | $0.55 | — | — | — | — | $88.03M |
| OKYOOKYO Pharma Ltd | $1.67 | — | 7.1x | — | -263.78% | $87.64M |
| RLYBRallybio Corp | $16.86 | 2.1x |
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.
Company description provided by Yahoo Finance.
| Profit margin | -401.00% | -262.29% | -315.90% | -401.00% | -649.22% | -4334.96% |
| ROE | -52.42% | -86.76% | -83.03% | -52.42% | -35.76% | -34.82% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.9x |
| — |
| 64.86% |
| $89.57M |
| ECORelectroCore, Inc. | $9.63 | — | — | — | — | $86.78M |
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |